Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest Acute myeloid leukemia Stories

2014-01-06 16:27:36

WHITE PLAINS, N.Y., Jan. 6, 2014 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) has awarded 21 new grants representing a total investment of $12.6 million to tackle six areas of high unmet medical need in the blood cancers. In response to requests for proposals (RFPs) from researchers in these six critical areas, LLS has awarded these grants under its Translational Research Program (TRP), an initiative designed to help accelerate the movement of promising discoveries from the lab...

2014-01-02 04:20:23

SEATTLE, Jan. 2, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that it has received notification from the U.S. Food and Drug Administration (FDA) that the partial clinical hold on tosedostat (IND 075503) has been removed and all studies underway may continue. Tosedostat is a first-in-class selective inhibitor of aminopeptidases, which are required by tumor cells to provide amino acids necessary for growth and tumor cell survival, and is under...

2013-12-18 13:10:26

Researchers at the Moffitt Cancer Center have discovered a control mechanism that can trigger the development of myelodysplastic syndromes (MDS), a group of blood cancers.  This finding may lead to therapies capable of preventing the progression of these diseases. MDS primarily affects older individuals, with approximately 12,000 new cases diagnosed each year. In MDS, a person’s blood is not able to make one or more types of healthy blood cells — red blood cells, white blood cells or...

2013-12-17 08:28:22

BERGEN, Norway, December 17, 2013 /PRNewswire/ -- BerGenBio AS ("BerGenBio" or the "Company"), an oncology biopharmaceutical company, announces that preclinical data demonstrating that BGB324 has potential application as a novel treatment for Chronic Myeloid Leukemia (CML), was presented in a poster at the Annual Meeting of the American Society of Hematology (ASH), which took place on December 7-10, 2013. The results suggest that BGB324 may be effective as monotherapy...

2013-12-16 12:25:23

CINCINNATI, Dec. 16, 2013 /PRNewswire-USNewswire/ -- Using genetic information initially uncovered in fruit fly studies, scientists have developed a unique therapeutic strategy that stops an aggressive and deadly form of leukemia in laboratory models of the disease. (Logo: http://photos.prnewswire.com/prnh/20110406/MM79025LOGO) Reporting their results Dec. 16 in the Journal of Clinical Investigation, researchers say their findings provide strong evidence for developing clinical...

2013-12-16 08:25:29

- Initial results for BL-8040 show substantial mobilization of cancer cells and signs of robust cancer cell death (apoptosis) - JERUSALEM, Dec. 16, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today promising initial results for its BL-8040 drug candidate in a Phase 2 clinical trial for patients with relapsed or refractory acute...

2013-12-10 12:33:00

Annual Conference Will Share Latest Advances in Blood Cancer Research and Clinical Trials SAN FRANCISCO, Dec. 10, 2013 /PRNewswire-USNewswire/ -- The Leukemia & Lymphoma Society's (LLS) Greater Bay Area Chapter will be hosting its annual Emerging Therapies & Survivorship Conference for blood cancer patients on Saturday, January 25, 2014, from 8:30 a.m. to 12:30 p.m. PT at the Hyatt Regency San Francisco. The Emerging Therapies & Survivorship Conference is a free event...

2013-12-10 08:29:38

- BL-8040 is currently in midst of Phase 2 study in AML patients, with partial results expected this month and final results expected in H2 2014 - JERUSALEM, Dec. 10, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced today that positive preclinical results of BL-8040 (formerly known as BKT-140), for the treatment of Acute Myeloid Leukemia (AML) and other hematological indications, have been presented as a poster at the...

2013-12-10 04:22:24

-- Interim Results of Tosedostat in Combination with Chemotherapy or Hypomethylating Agents in First-line Demonstrate 54 Percent Complete Response Rate and 12-Month Median Survival -- SEATTLE, Dec. 10, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced promising interim results from an investigator-initiated Phase 2 clinical trial of tosedostat in combination with cytarabine or decitabine in newly diagnosed older patients with acute myeloid...

2013-12-09 20:22:38

Four Presentations Including Results of Phase 2b Randomized, Open-Label Study of Lower Doses of Quizartinib in FLT3 ITD Positive Relapsed Refractory Acute Myeloid Leukemia (AML) Patients SAN DIEGO, Dec. 9, 2013 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced four oral presentations given at the 55(th) Annual ASH Conference in New...